28: Novo Nordisk's Bold Leap into Rare Diseases

Novo Nordisk is strategically expanding into rare diseases, shifting from its traditional focus on common chronic conditions, by significantly increasing R&D investment and executing key acquisitions to build a strong portfolio in blood, endocrine, and hemato-renal disorders. The company aims to achieve long-term leadership in this space through internal innovation, strategic partnerships, and further mergers and acquisitions. Hosted on Acast. See acast.com/privacy for more information.